---
http_interactions:
- request:
    method: get
    uri: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?api_key=<NCBI_API_KEY>&db=pubmed&id=37194105,37194085
    body:
      encoding: US-ASCII
      string: ''
    headers:
      Accept-Encoding:
      - gzip;q=1.0,deflate;q=0.6,identity;q=0.3
      Accept:
      - "*/*"
      User-Agent:
      - Ruby
  response:
    status:
      code: 200
      message: OK
    headers:
      Date:
      - Wed, 17 May 2023 09:04:11 GMT
      Server:
      - Finatra
      Strict-Transport-Security:
      - max-age=31536000; includeSubDomains; preload
      Content-Security-Policy:
      - upgrade-insecure-requests
      Referrer-Policy:
      - origin-when-cross-origin
      Ncbi-Sid:
      - 735AB243CA59769D_56C7SID
      Ncbi-Phid:
      - D0BD1EF10BD2F0D500005FF75AE813E5.1.1.m_3
      Content-Type:
      - text/xml; charset=UTF-8
      Cache-Control:
      - private
      X-Ratelimit-Limit:
      - '10'
      X-Ratelimit-Remaining:
      - '9'
      Access-Control-Allow-Origin:
      - "*"
      Access-Control-Expose-Headers:
      - X-RateLimit-Limit,X-RateLimit-Remaining
      Set-Cookie:
      - ncbi_sid=735AB243CA59769D_56C7SID; domain=.nih.gov; path=/; expires=Fri, 17
        May 2024 09:04:11 GMT
      X-Ua-Compatible:
      - IE=Edge
      X-Xss-Protection:
      - 1; mode=block
      Transfer-Encoding:
      - chunked
    body:
      encoding: ASCII-8BIT
      string: |-
        <?xml version="1.0" ?>
        <!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
        <PubmedArticleSet>
        <PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37194105</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1475-2867</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Cancer cell international</Title><ISOAbbreviation>Cancer Cell Int</ISOAbbreviation></Journal><ArticleTitle>Implications of CRNDE in prognosis, tumor immunity, and therapeutic sensitivity in low grade glioma patients.</ArticleTitle><Pagination><StartPage>93</StartPage><MedlinePgn>93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12935-023-02930-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Colorectal tumor differentially expressed (CRNDE) is specifically expressed in human brains and is the most highly expressed lncRNA in gliomas. Nevertheless, its implications in low grade glioma (LGG) are still indistinct. This study presented systematic analyses of CRNDE in LGG biology.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively retrieved TCGA, CGGC and GSE16011 LGG cohorts. Survival analysis was conducted for evaluating the prognostic significance of CRNDE in LGG. A CRNDE-based nomogram was established, and its predictive performance was verified. Signaling pathways underlying CRNDE were analyzed through ssGSEA and GSEA approaches. The abundance of immune cells and activity of cancer-immunity cycle were estimated with ssGSEA approach. Immune checkpoints, HLAs, chemokines, and immunotherapeutic response indicators (TIDE, and TMB) was quantified. U251 and SW1088 cells were transfected with specific shRNAs of CRNDE, and flow cytometry (apoptosis) and western blot (&#x3b2;-catenin and Wnt5a) assays were conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Up-regulated CRNDE was found in LGG, and was linked to unfavorable clinical outcomes. The CRNDE-based nomogram enabled to accurately predict patients' prognosis. High CRNDE expression was linked to more genomic variations, activity of tumorigenic pathways, tumor immunity (increase in infiltration of immune cells, expression of immune checkpoints, HLAs and chemokines, and cancer-immunity cycle), and therapeutic sensitivity. CRNDE knockdown mitigated malignant phenotypes of LGG cells.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study determined CRNDE as a novel predictor for patient prognosis, tumor immunity and therapeutic response in LGG. Assessment of CRNDE expression is a promising approach for predicting the therapeutic benefits of LGG patients.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jiang</LastName><ForeName>Yingchuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiuping</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, Fujian, China. li.qiuping@zs-hospital.sh.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. li.qiuping@zs-hospital.sh.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Biao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, Fujian, China. qi_biao@fudan.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Cell Int</MedlineTA><NlmUniqueID>101139795</NlmUniqueID><ISSNLinking>1475-2867</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRNDE</Keyword><Keyword MajorTopicYN="N">Low grade glioma</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Therapeutic sensitivity</Keyword><Keyword MajorTopicYN="N">Tumor immunity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37194105</ArticleId><ArticleId IdType="doi">10.1186/s12935-023-02930-w</ArticleId><ArticleId IdType="pii">10.1186/s12935-023-02930-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bornhorst M. New insights into the low-grade glioma tumor microenvironment for improved patient management. Neuro Oncol. 2022;24(1):27&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noab224</ArticleId><ArticleId IdType="pubmed">34515792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bale TA, Rosenblum MK: The,. WHO classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol. 2021;2022: e13060.</Citation></Reference><Reference><Citation>Klein M, Drijver AJ, van den Bent MJ, Bromberg JC, Hoang-Xuan K, Taphoorn MJB, Reijneveld JC, Ben Hassel M, Vauleon E, Eekers DBP, et al. Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033&#x2013;26033. Neuro Oncol. 2021;23(5):803&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noaa252</ArticleId><ArticleId IdType="pubmed">33130890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Xie F, Wu Y, Wang L, Bai Y, Long J, Wang X. Differential genes and scoring criteria among immunogenomic clusters of lower-grade gliomas. Int Immunopharmacol. 2021;101(Pt B): 108376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108376</ArticleId><ArticleId IdType="pubmed">34815191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang Y, Li J, Zhang Y, Yin H, Han B. CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett. 2015;367(2):122&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2015.03.027</ArticleId><ArticleId IdType="pubmed">25813405</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Liu M, Long W, Yuan J, Li H, Zhang C, Tang G, Jiang W, Yuan X, Wu M, et al. Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma. Cancer Cell Int. 2021;21(1):456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-021-02153-x</ArticleId><ArticleId IdType="pubmed">34454479</ArticleId><ArticleId IdType="pmc">8399846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Liu X, Wang P, Xue Y, Ma J, Qu C, Liu Y. CRNDE promotes malignant progression of glioma by attenuating miR-384/PIWIL4/STAT3 axis. Mol Ther. 2016;24(7):1199&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2016.71</ArticleId><ArticleId IdType="pubmed">27058823</ArticleId><ArticleId IdType="pmc">5088760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorokin M, Raevskiy M, Zottel A, &#x160;amec N, Skoblar Vidmar M, Matja&#x161;i&#x10d; A, Zupan A, Mlakar J, Suntsova M, Kuzmin DV, et al. Large-scale transcriptomics-driven approach revealed overexpression of CRNDE as a poor survival prognosis biomarker in glioblastoma. Cancers. 2021;13(14):3419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13143419</ArticleId><ArticleId IdType="pubmed">34298634</ArticleId><ArticleId IdType="pmc">8303503</ArticleId></ArticleIdList></Reference><Reference><Citation>Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8): e71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1507</ArticleId><ArticleId IdType="pubmed">26704973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.239244.118</ArticleId><ArticleId IdType="pubmed">30341162</ArticleId><ArticleId IdType="pmc">6211645</ArticleId></ArticleIdList></Reference><Reference><Citation>Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2011-12-4-r41</ArticleId><ArticleId IdType="pubmed">21527027</ArticleId><ArticleId IdType="pmc">3218867</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-7</ArticleId><ArticleId IdType="pubmed">23323831</ArticleId><ArticleId IdType="pmc">3618321</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, Birger C, Thorvaldsd&#xf3;ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2015.12.004</ArticleId><ArticleId IdType="pubmed">26771021</ArticleId><ArticleId IdType="pmc">4707969</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Niu X, Qiao X, Liu S, Ma H, Shi X, He X, Zhong M. Characterization of interplay between autophagy and ferroptosis and their synergistical roles on manipulating immunological tumor microenvironment in squamous cell carcinomas. Front Immunol. 2021;12: 739039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.739039</ArticleId><ArticleId IdType="pubmed">35185859</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId><ArticleId IdType="pmc">1239896</ArticleId></ArticleIdList></Reference><Reference><Citation>Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.12.019</ArticleId><ArticleId IdType="pubmed">28052254</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara K, Shahmoradgoli M, Mart&#xed;nez E, Vegesna R, Kim H, Torres-Garcia W, Trevi&#xf1;o V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3612</ArticleId><ArticleId IdType="pubmed">24113773</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Deng C, Pang B, Zhang X, Liu W, Liao G, Yuan H, Cheng P, Li F, Long Z, et al. TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res. 2018;78(23):6575&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-18-0689</ArticleId><ArticleId IdType="pubmed">30154154</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0136-1</ArticleId><ArticleId IdType="pubmed">30127393</ArticleId><ArticleId IdType="pmc">6487502</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955-961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1111</ArticleId><ArticleId IdType="pubmed">23180760</ArticleId></ArticleIdList></Reference><Reference><Citation>Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9): e107468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0107468</ArticleId><ArticleId IdType="pubmed">25229481</ArticleId><ArticleId IdType="pmc">4167990</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018;33(4):676-689.e673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2018.03.007</ArticleId><ArticleId IdType="pubmed">29622463</ArticleId><ArticleId IdType="pmc">6028190</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity. 2019;51(2):411&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.08.004</ArticleId><ArticleId IdType="pubmed">31433971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4191</ArticleId><ArticleId IdType="pubmed">27694933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang Y, Yang T, Xing H, Wang Y, Gao L, Guo X, Xing B, Wang Y, Ma W. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Brief Bioinform. 2021. https://doi.org/10.1093/bib/bbab032 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab032</ArticleId><ArticleId IdType="pubmed">34459479</ArticleId><ArticleId IdType="pmc">9630402</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Liu F, Li Y, Shen L. A 1p/19q codeletion-associated immune signature for predicting lower grade glioma prognosis. Cell Mol Neurobiol. 2022;42(3):709&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-020-00959-3</ArticleId><ArticleId IdType="pubmed">32894375</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Chen L, Xu H, Long S, Jiang J, Wei W, Niu X, Li X. Application of nanomaterials in diagnosis and treatment of glioblastoma. Front Chem. 2022;10:1063152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2022.1063152</ArticleId><ArticleId IdType="pubmed">36569956</ArticleId><ArticleId IdType="pmc">9780288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordell EC, Alghamri MS, Castro MG, Gutmann DH. T lymphocytes as dynamic regulators of glioma pathobiology. Neuro Oncol. 2022. https://doi.org/10.1093/neuonc/noac055 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noac055</ArticleId><ArticleId IdType="pubmed">35325210</ArticleId><ArticleId IdType="pmc">9165416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, et al. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022;132(3):e151239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI151239</ArticleId><ArticleId IdType="pubmed">34882581</ArticleId><ArticleId IdType="pmc">8803342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Wang H, Yu J, Yao X, Yang S, Li W, Xu L, Zhao L. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. Mol Cancer. 2021;20(1):6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-020-01299-y</ArticleId><ArticleId IdType="pubmed">33397371</ArticleId><ArticleId IdType="pmc">7780690</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin L, Zhou LQ, Liu C, Zeng F, Yuan YW, Zhou Q, Li SH, Wu Y, Wang JL, Wu DZ, et al. Transfer of LncRNA CRNDE in TAM-derived exosomes is linked with cisplatin resistance in gastric cancer. EMBO Rep. 2021;22(12): e52124.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202052124</ArticleId><ArticleId IdType="pubmed">34647680</ArticleId><ArticleId IdType="pmc">8647143</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, Yu ZW, Jia YH, Bai XF, Li L, et al. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/&#x3b2;-catenin signaling. Mol Cancer. 2017;16(1):9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-017-0583-1</ArticleId><ArticleId IdType="pubmed">28086904</ArticleId><ArticleId IdType="pmc">5237133</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao H, Song X, Kang T, Yan B, Feng L, Gao L, Ai L, Liu X, Yu J, Li H. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017;10:205&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S116178</ArticleId><ArticleId IdType="pubmed">28115855</ArticleId><ArticleId IdType="pmc">5221653</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Han B, Li Z, Sun D. Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression. Cell Cycle. 2019;18(19):2524&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2019.1652035</ArticleId><ArticleId IdType="pubmed">31416393</ArticleId><ArticleId IdType="pmc">6738913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Sun L, Dai X, Li T, Yan X, Zhang Y, Xiao H, Shen X, Huang G, Xiang W, et al. LncRNA CRNDE promotes ATG4B-mediated autophagy and alleviates the sensitivity of sorafenib in hepatocellular carcinoma cells. Front Cell Dev Biol. 2021;9: 687524.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.687524</ArticleId><ArticleId IdType="pubmed">34409031</ArticleId><ArticleId IdType="pmc">8365422</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie SC, Zhang JQ, Jiang XL, Hua YY, Xie SW, Qin YA, Yang YJ. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma. Cell Death Dis. 2020;11(8):676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-02853-8</ArticleId><ArticleId IdType="pubmed">32826865</ArticleId><ArticleId IdType="pmc">7442829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y, Zhang S, Cao W, Wan D, Sun L. Knockdown of LncRNA CRNDE suppresses proliferation and P-glycoprotein-mediated multidrug resistance in acute myelocytic leukemia through the Wnt/&#x3b2;-catenin pathway. Biosci Rep. 2020;40(6):BSR20193450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20193450</ArticleId><ArticleId IdType="pubmed">32426817</ArticleId><ArticleId IdType="pmc">7273914</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, Noro R, Seike M, Zeng C, Matsumoto M, Yoshikawa A, Nakamichi S, Sugano T, Hirao M, Matsuda K, et al. Long non-coding RNA CRNDE is involved in resistance to EGFR tyrosine kinase inhibitor in EGFR-mutant lung cancer via eIF4A3/MUC1/EGFR signaling. Int J Mol Sci. 2021;22(8):4005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22084005</ArticleId><ArticleId IdType="pubmed">33924522</ArticleId><ArticleId IdType="pmc">8070547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37194085</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1226-4601</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Biomaterials research</Title><ISOAbbreviation>Biomater Res</ISOAbbreviation></Journal><ArticleTitle>Emerging biomaterials for tumor immunotherapy.</ArticleTitle><Pagination><StartPage>47</StartPage><MedlinePgn>47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40824-023-00369-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The immune system interacts with cancer cells in various intricate ways that can protect the individual from overproliferation of cancer cells; however, these interactions can also lead to malignancy. There has been a dramatic increase in the application of cancer immunotherapy in the last decade. However, low immunogenicity, poor specificity, weak presentation efficiency, and off-target side effects still limit its widespread application. Fortunately, advanced biomaterials effectively contribute immunotherapy and play an important role in cancer treatment, making it a research hotspot in the biomedical field.</AbstractText><AbstractText Label="MAIN BODY" NlmCategory="METHODS">This review discusses immunotherapies and the development of related biomaterials for application in the field. The review first summarizes the various types of tumor immunotherapy applicable in clinical practice as well as their underlying mechanisms. Further, it focuses on the types of biomaterials applied in immunotherapy and related research on metal nanomaterials, silicon nanoparticles, carbon nanotubes, polymer nanoparticles, and cell membrane nanocarriers. Moreover, we introduce the preparation and processing technologies of these biomaterials (liposomes, microspheres, microneedles, and hydrogels) and summarize their mechanisms when applied to tumor immunotherapy. Finally, we discuss future advancements and shortcomings related to the application of biomaterials in tumor immunotherapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Research on biomaterial-based tumor immunotherapy is booming; however, several challenges remain to be overcome to transition from experimental research to clinical application. Biomaterials have been optimized continuously and nanotechnology has achieved continuous progression, ensuring the development of more efficient biomaterials, thereby providing a platform and opportunity for breakthroughs in tumor immunotherapy.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Minna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Qinglai</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Shiying</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xinming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Xinying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hemodialysis, the Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Gangcai</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Lanjie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China. leilanjie1988@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shisheng</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5874-6049</Identifier><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. lissdoctor@csu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biomater Res</MedlineTA><NlmUniqueID>101650636</NlmUniqueID><ISSNLinking>1226-4601</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomaterial</Keyword><Keyword MajorTopicYN="N">Cell membranes</Keyword><Keyword MajorTopicYN="N">Liposomes</Keyword><Keyword MajorTopicYN="N">Nanoparticles</Keyword><Keyword MajorTopicYN="N">Tumor immunotherapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37194085</ArticleId><ArticleId IdType="doi">10.1186/s40824-023-00369-8</ArticleId><ArticleId IdType="pii">10.1186/s40824-023-00369-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135:584&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000002108</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmy KY, Patel SA, Nahas GR, Rameshwar P. Cancer immunotherapy: accomplishments to date and future promise. Ther Deliv. 2013;4:1307&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde.13.88</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2019;176:677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.01.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan S, Huang Y, He M, Gao H. Advanced biomaterials for cell-specific modulation and restore of cancer immunotherapy. Adv Sci (Weinh). 2022;9: e2200027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202200027</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Y, Su M, Liu L, Tang Y, Pan Y, Sun J. Clinical application of cytokines in cancer immunotherapy. Drug Des Devel Ther. 2021;15:2269&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S308578</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao J, Fu YX. Cytokines that target immune killer cells against tumors. Cell Mol Immunol. 2020;17:722&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0481-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, P&#xe9;rez-Gracia JL, Rodr&#xed;guez-Ruiz ME, Ponz-Sarvise M, Casta&#xf1;&#xf3;n E, Melero I. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-018-0328-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Briukhovetska D, D&#xf6;rr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021;21:481&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-021-00363-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Wu Y, Bi J, Huang Y, Cheng Y, Li Y, Wu Y, Cao G, Tian Z. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cell Mol Immunol. 2022;19:192&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00786-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Eno J. Immunotherapy through the years. J Adv Pract Oncol. 2017;8:747&#x2013;53.</Citation></Reference><Reference><Citation>Atallah-Yunes SA, Robertson MJ. Cytokine based immunotherapy for cancer and lymphoma: biology challenges and future perspectives. Front Immunol. 2022;13: 872010.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.872010</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortara L, Balza E, Bruno A, Poggi A, Orecchia P, Carnemolla B. Anti-cancer therapies employing IL-2 Cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy. Front Immunol. 2018;9:2905.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02905</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen RM, Borden EC. Current status of interferons in the treatment of cancer. Oncology (Williston Park). 1992;6:19&#x2013;24 discussion 26, 29.</Citation></Reference><Reference><Citation>Ziegler-Heitbrock HW, Thiel E. Recombinant IFN-alpha in lymphomas. J Invest Dermatol. 1990;95:213s&#x2013;5s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1523-1747.ep12875789</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Tai YT, Ho MZG, Qiu L, Anderson KC. Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today&#x2019;s treat-to-target era. Exp Hematol Oncol. 2017;6:20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40164-017-0081-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa8172</ArticleId></ArticleIdList></Reference><Reference><Citation>Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-021-00588-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi S, Jie HB, Ferris RL. Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity. Semin Oncol. 2014;41:678&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminoncol.2014.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies. 2009;18:81&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/HAB-2009-0204</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11531280-000000000-00000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20:491&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-021-00079-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15:361&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3930</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurthy A, Jimeno A. Bispecific antibodies for cancer therapy: a review. Pharmacol Ther. 2018;185:122&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2017.12.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S151282</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santis R. Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy. MAbs. 2020;12:1725346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2020.1725346</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6:362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00670-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Suurs F. V, Lub-de Hooge M. N, de Vries E. G. E, de Groot D. J. A. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 2019;201:103&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2019.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kiecker F, Dippel E, Roesch A, Ziemer M, Conrad B, K&#xf6;rner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet. 2022;400:1117&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01654-3</ArticleId></ArticleIdList></Reference><Reference><Citation>George DJ, Spigel DR, Gordan LN, Kochuparambil ST, Molina AM, Yorio J, Rezazadeh Kalebasty A, McKean H, Tchekmedyian N, Tykodi SS, Zhang J, Askelson M, Johansen JL, Hutson TE. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. BMJ Open. 2022;12: e058396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-058396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert MP, Meindl-Beinker NM, Gutting T, Maenz M, Betge J, Schulte N, Zhan T, Weidner P, Burgermeister E, Hofheinz R, Vogel A, Angermeier S, Bolling C, de Wit M, Jakobs R, Karthaus M, Stocker G, Thuss-Patience P, Leidig T, Gaiser T, Kather JN, Haertel N. Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. Lancet Healthy Longev. 2022;3:e417&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(22)00116-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021;32:1245&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.06.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138:105&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12036</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, Roth J, Yi Q, Overwijk WW, Kwak LW. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med. 2014;20:676&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3560</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Workman CJ, Vignali DA. Targeting regulatory T cells in tumors. Febs j. 2016;283:2731&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.13656</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue G, Wang Z, Zheng N, Fang J, Mao C, Li X, Jin G, Ming X, Lu Y. Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells. Nat Biomed Eng. 2021;5:1306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-021-00799-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdin SM, Zaher DM, Arafa EA, Omar HA. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Cancers (Basel). 2018;10(2):32.</Citation></Reference><Reference><Citation>He CH, Li XM. Research progress in immunotherapy of head and neck squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022;57:82&#x2013;8.</Citation></Reference><Reference><Citation>Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00561</ArticleId></ArticleIdList></Reference><Reference><Citation>Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18:e731&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(17)30607-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-Ligand 1. Oncologist. 2016;21:643&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2015-0498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning YM, Suzman D, Maher VE, Zhang L, Tang S, Ricks T, Palmby T, Fu W, Liu Q, Goldberg KB, Kim G, Pazdur R. FDA Approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy. Oncologist. 2017;22:743&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2017-0087</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Ban X, Yang F, Li J, Cheng X, Zhang R, Huang X, Huang Y, Li Q, Qiu Y, Zheng M, Zhu X, Li J. Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer. J Immunother Cancer. 2022;10(5):e004338.</Citation></Reference><Reference><Citation>Xu Q, Wang J, Sun Y, Lin Y, Liu J, Zhuo Y, Huang Z, Huang S, Chen Y, Chen L, Ke M, Li L, Li Z, Pan J, Song Y, Liu R, Chen C. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. J Clin Oncol. 2022;40:1795&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.02091</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, Zhang Y, Chang Q, Zhang X, Dong Y, Teng J, Gao Z, Qiang H, Nie W, Zhao Y, Han Y, Chen Y, Han B. Phase 1b Study of Sintilimab Plus Anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol. 2021;16:643&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2020.11.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Li W, Wu X, Zhao F, Wang D, Wu H, Gu Y, Li X, Qian X, Hu J, Li C, Xia Y, Rao J, Dai X, Shao Q, Tang J, Li X, Shu Y. Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): a single-arm phase 2 study. Front Oncol. 2022;12: 909035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.909035</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Zhou J, Wang Y, Li M, Jiang H, Liu Y, Yin X, Ge M, Xiang X, Ying J, Huang J, Zhang YQ, Cheng Y, Huang Z, Yuan X, Han W, Yan D, Wang X, Liu P, Wang L, Zhang X, Luo S, Liu T, Shen L. Bifunctional anti-PD-L1/TGF-&#x3b2;RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. BMC Med. 2022;20:408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02605-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y, Mahmoodi M, Hassanzadeh A, Yazdanifar M, Stanley Chartrand M, Jarahian M. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. Front Oncol. 2021;11:673276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.673276</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Cao YJ. Adoptive cell therapy targeting neoantigens: a frontier for cancer research. Front Immunol. 2020;11:176.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew K. What is CAR T-cell therapy? Drug Ther Bull. 2021;59:73&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/dtb.2020.000040</ArticleId></ArticleIdList></Reference><Reference><Citation>Daher M, Melo Garcia L, Li Y, Rezvani K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunology. 2021;10:e1274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Wang L. The emerging world of TCR-T cell trials against cancer: a systematic review. Technol Cancer Res Treat. 2019;18:1533033819831068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533033819831068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, Pimiento J, Pilon-Thomas S, Sarnaik AA. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer. 2016;4:61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-016-0164-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Qian Y, Li Z, Li Y, Li B. Neoantigen-reactive T cell: An emerging role in adoptive cellular immunotherapy. MedComm. 2020;2021(2):207&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna S, Lowery FJ, Copeland AR, Bahadiroglu E, Mukherjee R, Jia L, Anibal JT, Sachs A, Adebola SO, Gurusamy D, Yu Z, Hill V, Gartner JJ, Li YF, Parkhurst M, Paria B, Kvistborg P, Kelly MC, Goff SL, Altan-Bonnet G, Robbins PF, Rosenberg SA. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 2020;370:1328&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb9847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauner K, Maisch P, Retz M. Side effects of chemotherapy. Urologe A. 2017;56:472&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00120-017-0338-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018;359:1037&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aar3246</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeng HM, Berzofsky JA. Strategies for developing and optimizing cancer vaccines. F1000Res. 2019;8:F1000 Faculty Rev-654.</Citation></Reference><Reference><Citation>Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-10-3126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen WS, Svrivastava AK, Batra L, Barsoumian H, Shirwan H. Current challenges for cancer vaccine adjuvant development. Expert Rev Vacc. 2018;17:207&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1434000</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Q, Zhang CD, Wu XH. Therapeutic cancer vaccines: From initial findings to prospects. Immunol Lett. 2018;196:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2018.01.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Waki K, Yamada A. Personalized peptide vaccine for cancer treatment; now and its future. Nihon Rinsho. 2017;75:251&#x2013;6.</Citation></Reference><Reference><Citation>Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, Li G, Xiong W, Zeng Z. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18:128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-019-1055-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta SL, Basu S, Soni V, Jaiswal RK. Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep. 2022;49:9903&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-022-07525-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladak RJ, He AJ, Huang YH, Ding Y. The current landscape of mRNA vaccines against viruses and cancer-a mini review. Front Immunol. 2022;13: 885371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.885371</ArticleId></ArticleIdList></Reference><Reference><Citation>Shou J, Mo F, Zhang S, Lu L, Han N, Liu L, Qiu M, Li H, Han W, Ma D, Guo X, Guo Q, Huang Q, Zhang X, Ye S, Pan H, Chen S, Fang Y. Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy. Front Immunol. 2022;13:1000681.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1000681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18:498&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0014-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Huang J, Tang J, Hu S, Luo S, Luo Z, Zhou F, Tan S, Ying J, Chang Q, Zhang R, Geng C, Wu D, Gu X, Liu B. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial. J Immunother Cancer. 2021;9(4):e002224.</Citation></Reference><Reference><Citation>Manyam M, Stephens AJ, Kennard JA, LeBlanc J, Ahmad S, Kendrick JE, Holloway RW. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2021;163:481&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2021.10.069</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy DG, Geoffroy K, Marguerie M, Khan ST, Martin NT, Kmiecik J, Bobbala D, Aitken AS, de Souza CT, Stephenson KB, Lichty BD, Auer RC, Stojdl DF, Bell JC, Bourgeois-Daigneault MC. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nat Commun. 2021;12:2626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22929-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake CG. Combination immunotherapy approaches. Ann Oncol. 2012;23(Suppl 8):viii41-46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mds262</ArticleId></ArticleIdList></Reference><Reference><Citation>Gellrich FF, Schmitz M, Beissert S, Meier F. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update. J Clin Med. 2020;9(1):223.</Citation></Reference><Reference><Citation>Joshi S, Durden DL. Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system. J Oncol. 2019;2019:5245034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/5245034</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14:156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-021-01164-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei K, Tang L. Surgery-free injectable macroscale biomaterials for local cancer immunotherapy. Biomater Sci. 2019;7:733&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C8BM01470A</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S, Luo Z, Li Z, Wang Y, Tao J, Gong C, Liu X. Improving cancer immunotherapy outcomes using biomaterials. Angew Chem Int Ed Engl. 2020;59:17332&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202002780</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L, Xu J, Yang Z, Tong R, Dong Z, Wang C, Leong KW. Engineered biomaterials for cancer immunotherapy. MedComm. 2020;2020(1):35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.8</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang R, Liu L, He H, Chen Z, Han Z, Luo Z, Wu Z, Zheng M, Ma Y, Cai L. Oxygen-boosted immunogenic photodynamic therapy with gold nanocages@manganese dioxide to inhibit tumor growth and metastases. Biomaterials. 2018;177:149&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2018.05.051</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M, Duan X, Cai Y, Zhang F, Jiang S, Han S, Shen J, Shuai X. Multifunctional nanoregulator reshapes immune microenvironment and enhances immune memory for tumor immunotherapy. Adv Sci (Weinh). 2019;6:1900037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.201900037</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Lee JS, Kim D, Zhu L. Exploration of zinc oxide nanoparticles as a multitarget and multifunctional anticancer nanomedicine. ACS Appl Mater Interfaces. 2017;9:39971&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.7b11219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Shin JB, Park BC, Lee JW, Byun SW, Jang NY, Kim YJ, Kim Y, Kim YK, Cho NH. Application of radially grown ZnO nanowires on poly-l-lactide microfibers complexed with a tumor antigen for cancer immunotherapy. Nanoscale. 2019;11:4591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C8NR08704K</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wu F, Men K, Huang R, Zhou B, Zhang R, Zou R, Yang L. Modified Fe(3)O(4) magnetic nanoparticle delivery of CpG inhibits tumor growth and spontaneous pulmonary metastases to enhance immunotherapy. Nanoscale Res Lett. 2018;13:240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11671-018-2661-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Zhao X, Cheng Y, Guo X, Yuan W. Iron oxide nanoparticles-based vaccine delivery for cancer treatment. Mol Pharm. 2018;15:1791&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.7b01103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Liang H, Ge Y, Ding W, Chen Q, Zhang T, Xiao L, Li Y, Dong J, He X, Xue F, Jiang L. Precisely targeted nano-controller of PD-L1 Level for non-small cell lung cancer spinal metastasis immunotherapy. Adv Healthc Mater. 2022;11: e2200938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202200938</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Yang F, Yang H, Xu Y, Song SJ, Meng Y, Wei ST, Wan T, Zhou Y, Zhou B, Kuang J, Yu T, Qiu WX. Enhanced immunotherapy based on combining the pro-phagocytosis and anti-phagocytosis checkpoint blockade for tumor eradication. J Med Chem. 2022;65:14832&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c01351</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Shou X, Zhang Y, Li Z, Wu G, Wu D, Wu J, Shi S, Wang S. Cell membrane-encapsulated magnetic nanoparticles for enhancing natural killer cell-mediated cancer immunotherapy. Nanomedicine. 2021;32: 102333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2020.102333</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Pang C, Song C, Qian J, Feola S, Cerullo V, Fan L, Yu H, Lehto VP. Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy. Acta Biomater. 2022;152:473&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2022.08.073</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Wang X, Sun L, Yamazaki A, Li X. Tumor microenvironment regulation - enhanced radio - immunotherapy. Biomater Adv. 2022;138: 212867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioadv.2022.212867</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang N, Wei L, Tao Y, Jin W, Bin Y, DingHua Z. Construction of Durvalumab/carbon nanotube/PEI/aptamer-siRNA chimera for the immunotherapy of hepatocellular carcinoma. Biomed Mater. 2022;17(2). https://doi.org/10.1088/1748-605X/ac5414 .</Citation></Reference><Reference><Citation>Dong Z, Wang Q, Huo M, Zhang N, Li B, Li H, Xu Y, Chen M, Hong H, Wang Y. Mannose-modified multi-walled carbon nanotubes as a delivery nanovector optimizing the antigen presentation of dendritic cells. ChemistryOpen. 2019;8:915&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/open.201900126</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q, Gong C, Gu F, Wang Z, Hu C, Zhang L, Qiang L, Ding X, Gao S, Gao Y. Functionalized multi-walled carbon nanotubes for targeting delivery of immunostimulatory CpG oligonucleotides against prostate cancer. J Biomed Nanotechnol. 2018;14:1613&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1166/jbn.2018.2605</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez AL, Lustgarten J. Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine. 2010;28:1383&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.10.153</ArticleId></ArticleIdList></Reference><Reference><Citation>Coumes F, Huang CY, Huang CH, Coudane J, Domurado D, Li S, Darcos V, Huang MH. Design and development of immunomodulatory antigen delivery systems based on Peptide/PEG-PLA conjugate for tuning immunity. Biomacromol. 2015;16:3666&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biomac.5b01150</ArticleId></ArticleIdList></Reference><Reference><Citation>Thauvin C, Widmer J, Mottas I, Hocevar S, All&#xe9;mann E, Bourquin C, Delie F. Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: a kinetic study. Eur J Pharm Biopharm. 2019;139:253&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2019.04.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Xu L, Liang C, Wang C, Peng R, Liu Z. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016;7:13193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13193</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Yang Z, Dong Z, Gong Y, Hao Y, Tian L, Yang X, Liu Z, Feng L. CaCO(3)-Assisted Preparation of pH-responsive immune-modulating nanoparticles for augmented chemo-immunotherapy. Nanomicro Lett. 2020;13:29.</Citation></Reference><Reference><Citation>Koerner J, Horvath D, Herrmann VL, MacKerracher A, Gander B, Yagita H, Rohayem J, Groettrup M. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nat Commun. 2021;12:2935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23244-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Podojil JR, Cogswell AC, Chiang MY, Eaton V, Ifergan I, Neef T, Xu D, Meghani KA, Yu Y, Orbach SM, Murthy T, Boyne MT, Elhofy A, Shea LD, Meeks JJ, Miller SD. Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy. Front Immunol. 2022;13: 887649.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.887649</ArticleId></ArticleIdList></Reference><Reference><Citation>Dane EL, Belessiotis-Richards A, Backlund C, Wang J, Hidaka K, Milling LE, Bhagchandani S, Melo MB, Wu S, Li N, Donahue N, Ni K, Ma L, Okaniwa M, Stevens MM, Alexander-Katz A, Irvine DJ. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nat Mater. 2022;21:710&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41563-022-01251-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Hu M, Wang S, Wang Q, Lu H, Wang F, Wang L, Peng D, Chen W. Nano-delivery of salvianolic acid B induces the quiescence of tumor-associated fibroblasts via interfering with TGF-&#x3b2;1/Smad signaling to facilitate chemo- and immunotherapy in desmoplastic tumor. Int J Pharm. 2022;623: 121953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2022.121953</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang MY, Zhang MJ, Qiu W, Xiao Y, Ye MJ, Xue P, Kang YJ, Sun ZJ, Xu Z. Stepwise size shrinkage cascade-activated supramolecular prodrug boosts antitumor immunity by eliciting pyroptosis. Adv Sci (Weinh). 2022;9: e2203353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202203353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Dong Z, Lou F, Yin Y, Zhang J, Wen H, Lu T, Wang Y. Phenylboronic ester-modified polymeric nanoparticles for promoting TRP2 peptide antigen delivery in cancer immunotherapy. Drug Deliv. 2022;29:2029&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10717544.2022.2086941</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Y, Mao J, Leng X, Zhu L, Rui X, Jin Z, Jiang H, Liu H, Zhang F, Bi X, Chen Z, Wang J. Co-delivery of proanthocyanidin and mitoxantrone induces synergistic immunogenic cell death to potentiate cancer immunotherapy. Biomater Sci. 2022;10:4549&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2BM00611A</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong Q, Li J, Xiao X, Du X, Yuan Y. Self-amplified chain-shattering cinnamaldehyde-based poly(thioacetal) boosts cancer chemo-immunotherapy. Acta Biomater. 2022. https://doi.org/10.1016/j.actbio.2022.09.066 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2022.09.066</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Zhou D, Dai Y, Li Y, Wu J, Liu Q, Deng X. Construction of PEI-EGFR-PD-L1-siRNA dual functional nano-vaccine and therapeutic efficacy evaluation for lung cancer. Thorac Cancer. 2022;13:2941&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1759-7714.14618</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Wang C, Wang H, Zhang Z, Yang X, Dong Y, Ma L, Luo J. Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy. BMC Med. 2022;20:411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02614-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Z, Wang D, Wang C, Chen Z, Huang C, Yang Y, Xie L, Zhang L, Xu L, Zhang MR, Hu K, Li Z, Luo L. PEIGel: a biocompatible and injectable scaffold with innate immune adjuvanticity for synergized local immunotherapy. Mater Today Bio. 2022;15: 100297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mtbio.2022.100297</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Deeb NM, Ibrahim OM, Mohamed MA, Farag MMS, Farrag AA, El-Aassar MR. Alginate/&#x3ba;-carrageenan oral microcapsules loaded with Agaricus bisporus polysaccharides MH751906 for natural killer cells mediated colon cancer immunotherapy. Int J Biol Macromol. 2022;205:385&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.02.058</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Heo R, Song SH, Song KH, Shin JM, Oh SJ, Lee HJ, Chung JE, Park JH, Kim TW. PD-L1 siRNA-hyaluronic acid conjugate for dual-targeted cancer immunotherapy. J Control Release. 2022;346:226&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2022.04.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Zhu X, Zhou X, Wang X, Zhai W, Li B, Du J, Li G, Sui X, Wu Y, Zhai M, Qi Y, Chen G, Gao Y. An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy. J Control Release. 2021;334:376&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2021.04.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X, Li L, Li X, He T, Gong S, Zhu S, Zhang M, Wu Q, Gong C. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response. Theranostics. 2021;11:6936&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.58173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ornell KJ, Taylor JS, Zeki J, Ikegaki N, Shimada H, Coburn JM, Chiu B. Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model. Cancer Med. 2020;9:2891&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.2936</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan M, Chen Y, Guo Y, Yang C, Liu M, Guo D, Wang Z, Cao Y, Ran H. A low-intensity focused ultrasound-assisted nanocomposite for advanced triple cancer therapy: local chemotherapy, therapeutic extracellular vesicles and combined immunotherapy. Biomater Sci. 2020;8:6703&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0BM00804D</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo W, Yang X, Wang B, Cao L, Fang Z, Li Z, Liu H, Liang XJ, Zhang J, Jin Y. Biomineralized hydrogel DC vaccine for cancer immunotherapy: a boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment. Biomaterials. 2022;288: 121722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2022.121722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei F, Cai J, Lyu R, Shen H, Xu Y, Wang J, Shuai Y, Xu Z, Mao C, Yang M. Efficient Tumor Immunotherapy through a single injection of injectable antigen/adjuvant-loaded macroporous silk fibroin microspheres. ACS Appl Mater Interfaces. 2022;14:42950&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.2c11286</ArticleId></ArticleIdList></Reference><Reference><Citation>Du YN, Wei Q, Zhao LJ, Fan CQ, Guo LR, Ye JF, Li Y. Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy. Biomed Pharmacother. 2022;151: 113110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113110</ArticleId></ArticleIdList></Reference><Reference><Citation>Suraiya AB, Evtimov VJ, Truong VX, Boyd RL, Forsythe JS, Boyd NR. Micro-hydrogel injectables that deliver effective CAR-T immunotherapy against 3D solid tumor spheroids. Transl Oncol. 2022;24: 101477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2022.101477</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Qu M, Kim HJ, Zhou X, Jiang X, Chen Y, Zhu J, Ren L, Wolter T, Kang H, Xu C, Gu Z, Sun W, Khademhosseini A. A Shear-thinning biomaterial-mediated immune checkpoint blockade. ACS Appl Mater Interfaces. 2022;14:35309&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.2c06137</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X, Ye X, Wang C, Xing C, Miao Q, Xie Z, Chen X, Zhang X, Zhang H, Mei L. Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation. J Control Release. 2019;296:150&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2019.01.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong J, Wu M, Chen J, Liu Y, Chen Y, Fan G, Liu Y, Cheng J, Wang Z, Wang S, Liu Y, Zhang W. Cancer-erythrocyte hybrid membrane-camouflaged magnetic nanoparticles with enhanced photothermal-immunotherapy for ovarian cancer. ACS Nano. 2021;15:19756&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.1c07180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahmani B, Gong H, Luk BT, Haushalter KJ, DeTeresa E, Previti M, Zhou J, Gao W, Bui JD, Zhang L, Fang RH, Zhang J. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. Nat Commun. 1999;2021:12.</Citation></Reference><Reference><Citation>Yan H, Zhang Y, Zhang Y, Li Y, Kong X, Liu D, Li J, Xi Y, Ji J, Ye L, Zhai G. A ROS-responsive biomimetic nano-platform for enhanced chemo-photodynamic-immunotherapy efficacy. Biomater Sci. 2022;10:6583&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2BM01291J</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R, An Y, Jia W, Wang Y, Wu Y, Zhen Y, Cao J, Gao H. Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer. J Control Release. 2020;321:589&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.02.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Song M, Du Y, Yu Y, Li C, Han Y, Yan F, Shi Z, Feng S. Tumor-associated-macrophage-membrane-coated nanoparticles for improved photodynamic immunotherapy. Nano Lett. 2021;21:5522&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.1c00818</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu X, Zhang M, Wei A, Yin F, Wang Y, Hu K, Jiang J. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases. Nanoscale. 2021;13:8998&#x2013;9008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0NR08024A</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Zhang C, Liu M, Huang J, Jin X, Zhu C, Lv M, Yang N, Chen S, Shao M, Du X, Feng G. Nucleus-targeting manganese dioxide nanoparticles coated with the human umbilical cord mesenchymal stem cell membrane for cancer cell therapy. ACS Appl Mater Interfaces. 2023;15(8):10541-53.</Citation></Reference><Reference><Citation>Johnson DT, Zhou J, Kroll AV, Fang RH, Yan M, Xiao C, Chen X, Kline J, Zhang L, Zhang DE. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia. 2022;36:994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01432-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochyl LJ, Bazzill JD, Park C, Xu Y, Kuai R, Moon JJ. PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy. Biomaterials. 2018;182:157&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2018.08.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhao R, Cheng K, Zhang K, Wang Y, Zhang Y, Li Y, Liu G, Xu J, Xu J, Anderson GJ, Shi J, Ren L, Zhao X, Nie G. Bacterial Outer membrane vesicles presenting programmed death 1 for improved cancer immunotherapy via immune activation and checkpoint inhibition. ACS Nano. 2020;14:16698&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c03776</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou MZ, Li ZH, Bai XF, Liu CJ, Zhang XZ. Hybrid Vesicles Based on autologous tumor cell membrane and bacterial outer membrane to enhance innate immune response and personalized tumor immunotherapy. Nano Lett. 2021;21:8609&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.1c02482</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S, Annu, Chaudhry SA, Ikram S. A review on biogenic synthesis of ZnO nanoparticles using plant extracts and microbes: A prospect towards green chemistry. J Photochem Photobiol B. 2017;166:272&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphotobiol.2016.12.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry N, Dwivedi S, Chaudhry V, Singh A, Saquib Q, Azam A, Musarrat J. Bio-inspired nanomaterials in agriculture and food: current status, foreseen applications and challenges. Microb Pathog. 2018;123:196&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2018.07.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa M, Watanabe C, Yoshinaga N, Fujiwara K. Cell-size space regulates the behavior of confined polymers: from nano- and micromaterials science to biology. Langmuir. 2022;38:11811&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.langmuir.2c01397</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu D, Zhu XH, Ren SZ, Lu YD, Zhu HL. Manganese dioxide (MnO(2)) based nanomaterials for cancer therapies and theranostics. J Drug Target. 2021;29:911&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1061186X.2020.1815209</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P, Zhu Y, Yang X, Shen J, Jiang X, Zong J, Li C. Multifunctional MnO2 nanosheet-modified Fe3O4@SiO2/NaYF4:Yb, Er nanocomposites as novel drug carriers. Dalton Trans. 2014;43:451&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C3DT52066H</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Ye D, Wu M, Chen H, Zhang L, Shi J, Wang L. Break-up of two-dimensional MnO2 nanosheets promotes ultrasensitive pH-triggered theranostics of cancer. Adv Mater. 2014;26:7019&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201402572</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Fan H, Zhou G, Bai H, Liang H, Wang R, Zhang X, Tan W. Activatable fluorescence/MRI bimodal platform for tumor cell imaging via MnO2 nanosheet-aptamer nanoprobe. J Am Chem Soc. 2014;136:11220&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja5029364</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng R, Xie X, Vendrell M, Chang YT, Liu X. Intracellular glutathione detection using MnO(2)-nanosheet-modified upconversion nanoparticles. J Am Chem Soc. 2011;133:20168&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja2100774</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M, Liu T, Shi C, Zhang X, Chen X. Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia. ACS Nano. 2016;10:633&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.5b06779</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-13-0992</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Xu L, Chao Y, Xu J, Sun X, Wu Y, Peng R, Liu Z. Hollow MnO(2) as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun. 2017;8:902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01050-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, Dinh TK, Lee YA, Wang FN, Sung YC, Yu PL, Chiu SC, Shih YC, Wu CY, Huang YD, Wang J, Lu TT, Wan D, Chen Y. Nanoparticle delivery of MnO(2) and antiangiogenic therapy to overcome hypoxia-driven tumor escape and suppress hepatocellular carcinoma. ACS Appl Mater Interfaces. 2020;12:44407&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.0c08473</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F, Tang Y, Liu WL, Zou MZ, Huang C, Liu CJ, Zhang XZ. Intra/extracellular lactic acid exhaustion for synergistic metabolic therapy and immunotherapy of tumors. Adv Mater. 2019;31: e1904639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201904639</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou L, Tian C, Yan Y, Zhang L, Zhang H, Zhang Z. Manganese-based nanoactivator optimizes cancer immunotherapy via enhancing innate immunity. ACS Nano. 2020;14:3927&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.9b06111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding B, Yue J, Zheng P, Ma P, Lin J. Manganese oxide nanomaterials boost cancer immunotherapy. J Mater Chem B. 2021;9:7117&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1TB01001H</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen JW, Martinez E, Louka P, Wingett DG. Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications. Expert Opin Drug Deliv. 2010;7:1063&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2010.502560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu M, Sadhukhan P, Ghosh N, Chatterjee S, Manna P, Das J, Sil PC. pH-responsive and targeted delivery of curcumin via phenylboronic acid-functionalized ZnO nanoparticles for breast cancer therapy. J Adv Res. 2019;18:161&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2019.02.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Nayak TR, Hong H, Cai W. Biomedical applications of zinc oxide nanomaterials. Curr Mol Med. 2013;13:1633&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1566524013666131111130058</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong HM. ZnO nanoparticles applied to bioimaging and drug delivery. Adv Mater. 2013;25:5329&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201301732</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabil A, Elshemy MM, Asem M, Abdel-Motaal M, Gomaa HF, Zahran F, Uto K, Ebara M. Zinc oxide nanoparticle synergizes sorafenib anticancer efficacy with minimizing its cytotoxicity. Oxid Med Cell Longev. 2020;2020:1362104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/1362104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Hu H, Yan J, Zhang C, Li Y, Wang M, Tan W, Liu J, Pan Y. Multifunctional porous iron oxide nanoagents for MRI and photothermal/chemo synergistic therapy. Bioconjug Chem. 2018;29:1283&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.8b00052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang RM, Fu CP, Fang JZ, Xu XD, Wei XH, Tang WJ, Jiang XQ, Zhang LM. Hyaluronan-modified superparamagnetic iron oxide nanoparticles for bimodal breast cancer imaging and photothermal therapy. Int J Nanomedicine. 2017;12:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S121249</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CX, Zhang Y, Dong X, Zhang L, Liu MD, Li B, Zhang MK, Feng J, Zhang XZ. Artificially reprogrammed macrophages as tumor-tropic immunosuppression-resistant biologics to realize therapeutics production and immune activation. Adv Mater. 2019;31: e1807211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201807211</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Iqbal MZ, Liu C, Xing J, Akakuru OU, Fang Q, Li Z, Dai Y, Li A, Guan Y, Wu A. Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma. Biomaterials. 2019;223: 119464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2019.119464</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng HW, Tsao HY, Chiang CS, Chen SY. Advances in magnetic nanoparticle-mediated cancer immune-theranostics. Adv Healthc Mater. 2021;10: e2001451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202001451</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Choi B, Li W, Kim DH. Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy. Nat Commun. 2020;11:3637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17380-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou AE, Hinckley JA, Khaitan R, Varsano N, Wang J, Malarkey HF t, Hernandez CJ, Williams RM, Estroff LA, Weiner S, Addadi L, Wiesner UB, Fischbach C. Fluorescent Silica Nanoparticles to Label Metastatic Tumor Cells in Mineralized Bone Microenvironments. Small. 2021;17:e2001432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smll.202001432</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HY, Cao PP, He ZY, He XW, Li WY, Li YH, Zhang YK. Targeted imaging and targeted therapy of breast cancer cells via fluorescent double template-imprinted polymer coated silicon nanoparticles by an epitope approach. Nanoscale. 2019;11:17018&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9NR04655K</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu K, Liu C, Wang G, Yang W, Fan K, Lazarouk S, Labunov V, Dong L, Li D, Yang X. A highly sensitive silicon nanowire array sensor for joint detection of tumor markers CEA and AFP. Biomater Sci. 2022;10:3823&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2BM00555G</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui M, Liu S, Song B, Guo D, Wang J, Hu G, Su Y, He Y. Fluorescent silicon nanorods-based nanotheranostic agents for multimodal imaging-guided photothermal therapy. Nanomicro Lett. 2019;11:73.</Citation></Reference><Reference><Citation>Guo D, Ji X, Peng F, Zhong Y, Chu B, Su Y, He Y. Photostable and biocompatible fluorescent silicon nanoparticles for imaging-guided co-delivery of siRNA and doxorubicin to drug-resistant cancer cells. Nanomicro Lett. 2019;11:27.</Citation></Reference><Reference><Citation>Chu B, Song B, Ji X, Su Y, Wang H, He Y. Fluorescent Silicon nanorods-based ratiometric sensors for long-term and real-time measurements of intracellular pH in live cells. Anal Chem. 2017;89:12152&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.7b02791</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamaeva V, Sahlgren C, Lind&#xe9;n M. Mesoporous silica nanoparticles in medicine&#x2013;recent advances. Adv Drug Deliv Rev. 2013;65:689&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2012.07.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Jo C, Lim WG, Jung S, Lee YM, Lim J, Lee H, Lee J, Kim WJ. Programmed nanoparticle-loaded nanoparticles for deep-penetrating 3D cancer therapy. Adv Mater. 2018;e1707557.</Citation></Reference><Reference><Citation>Sandoval S, Tobias G, Flahaut E. Structure of inorganic nanocrystals confined within carbon nanotubes. Inorganica Chimica Acta. 2019;492:66-75.</Citation></Reference><Reference><Citation>Safari J, Zarnegar Z. Advanced drug delivery systems: Nanotechnology of health design A review. J Saudi Chem Soc. 2014;18:85&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jscs.2012.12.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanone S, Andujar P, Kermanizadeh A, Boczkowski J. Determinants of carbon nanotube toxicity. Adv Drug Deliv Rev. 2013;65:2063&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2013.07.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikholeslam M, Wheeler SD, Duke KG, Marsden M, Pritzker M, Chen P. Peptide and peptide-carbon nanotube hydrogels as scaffolds for tissue &amp; 3D tumor engineering. Acta Biomater. 2018;69:107&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2017.12.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindumathi R, Jagannatham MV, Haridoss P, Sharma CP. Novel nano-cocoon like structures of polyethylene glycol&#x2013;multiwalled carbon nanotubes for biomedical applications. Nano-Structures Nano-Objects. 2018;13:30&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nanoso.2017.11.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J, Shen S, Wang D, Xi Z, Guo L, Pang Z, Qian Y, Sun X, Jiang X. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials. 2012;33:3324&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2012.01.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Zhao J, Du Z. Density-functional-theory-based study of interaction of DNA/RNA nucleobases with hydroxyl- and carboxyl-functionalized armchair (6,6)CNT. Comput Theor Chem. 2017;1102:60&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.comptc.2017.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis AP, Devasena T. Toxicity of carbon nanotubes: a review. Toxicol Ind Health. 2018;34:200&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0748233717747472</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H, Gao S, Song D, Liu Y, Chen X. Intratumorally CpG immunotherapy with carbon nanotubes inhibits local tumor growth and liver metastasis by suppressing the epithelial-mesenchymal transition of colon cancer cells. Anticancer Drugs. 2021;32:278&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CAD.0000000000001000</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X, Li Y, Zhang Z, Zhang C, Hu J, Wang X, Zhang R, Yang J, Zhou L, Zhang H, Liu M, Zhou J. An electrochemical biosensor for the assessment of tumor immunotherapy based on the detection of immune checkpoint protein programmed death ligand-1. Biosens Bioelectron. 2022;207: 114166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bios.2022.114166</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, Jay SM, Demento SL, Agawu A, Licona Limon P, Ferrandino AF, Gonzalez D, Habermann A, Flavell RA, Fahmy TM. Combination delivery of TGF-&#x3b2; inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater. 2012;11:895&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmat3355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai SK, Suk JS, Pace A, Wang YY, Yang M, Mert O, Chen J, Kim J, Hanes J. Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. Biomaterials. 2011;32:6285&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2011.05.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu M, Fischer D, Kissel T. Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J Gene Med. 2005;7:992&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgm.773</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao C, Xiao Y, Chen K, Li P, Wu Y, Li X, Zuo Y. Synergistic modification of polylactic acid by oxidized straw fibers and degradable elastomers: A green composite with good strength and toughness. Int J Biol Macromol. 2022;221:773&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.09.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Li B, Chen G, Ye X, Zhang Y. Nano tantalum-coated 3D printed porous polylactic acid/beta-tricalcium phosphate scaffolds with enhanced biological properties for guided bone regeneration. Int J Biol Macromol. 2022;221:371&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.09.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarna C, Rodr&#xed;guez-Fabi&#xe0; S, Echtermeyer AT, Chinga-Carrasco G. Influence of Compounding Parameters on the Tensile Properties and Fibre Dispersion of Injection-Moulded Polylactic Acid and Thermomechanical Pulp Fibre Biocomposites. Polymers (Basel). 2022;14(20):4432.</Citation></Reference><Reference><Citation>Yang JY, Kim DK, Han W, Park JY, Kim KW, Kim BJ. Effect of Nucleating Agents Addition on Thermal and Mechanical Properties of Natural Fiber-Reinforced Polylactic Acid Composites. Polymers (Basel). 2022;14(20):4263.</Citation></Reference><Reference><Citation>Tyler B, Gullotti D, Mangraviti A, Utsuki T, Brem H. Polylactic acid (PLA) controlled delivery carriers for biomedical applications. Adv Drug Deliv Rev. 2016;107:163&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2016.06.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125:193&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2007.09.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha CV, Gon&#xe7;alves V, da Silva MC, Ba&#xf1;obre-L&#xf3;pez M, Gallo J. PLGA-Based Composites for Various Biomedical Applications. Int J Mol Sci. 2022;23(4):2034.</Citation></Reference><Reference><Citation>Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, Ferguson DM, Griffith TS, Panyam J. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials. 2018;164:38&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2018.02.034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Li J, Song T. Poly lactic-co-glycolic acid-based nanoparticles as delivery systems for enhanced cancer immunotherapy. Front Chem. 2022;10: 973666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2022.973666</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker R, Dembek C, White LA, Garrison LP. The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2012;12:775&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erp.12.65</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai J, Dong X, Wang Q, Lou X, Xia F, Wang S. PEG-Polymer encapsulated aggregation-induced emission nanoparticles for tumor theranostics. Adv Healthc Mater. 2021;10: e2101036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202101036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding M, Liu W, Gref R. Nanoscale MOFs: From synthesis to drug delivery and theranostics applications. Adv Drug Deliv Rev. 2022;190: 114496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2022.114496</ArticleId></ArticleIdList></Reference><Reference><Citation>Delyanee M, Akbari S, Solouk A. Amine-terminated dendritic polymers as promising nanoplatform for diagnostic and therapeutic agents&#x2019; modification: a review. Eur J Med Chem. 2021;221: 113572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2021.113572</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Zheng Q, Deng Q, Wang Y, Yang H, Shen J, Liu Y, Zhou J. A Dual functional drug delivery system that combines photothermal therapy and immunotherapy to treat tumors. Mol Pharm. 2022;19:1449&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.1c00999</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Xu Y, Ma S, Wang Y, Huang Z, Qu H, Yao H, Zhang Y, Wu G, Huang L, Song W, Tang Z, Chen X. A minimalist binary vaccine carrier for personalized postoperative cancer vaccine therapy. Adv Mater. 2022;34: e2109254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202109254</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D, Qian H, Qiao H, Chen W, Feijen J, Zhong Z. Bioresponsive functional nanogels as an emerging platform for cancer therapy. Expert Opin Drug Deliv. 2018;15:703&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425247.2018.1497607</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed M, Gao J, Shi Y, Lammers T, Yu H. Engineering Nanoparticles to reprogram the tumor immune microenvironment for improved cancer immunotherapy. Theranostics. 2019;9:7981&#x2013;8000.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.37568</ArticleId></ArticleIdList></Reference><Reference><Citation>Estey T, Kang J, Schwendeman SP, Carpenter JF. BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems. J Pharm Sci. 2006;95:1626&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.20625</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Prestwich GD. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets. 2002;2:209&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568009023333836</ArticleId></ArticleIdList></Reference><Reference><Citation>Garanger E, Lecommandoux S. Emerging opportunities in bioconjugates of Elastin-like polypeptides with synthetic or natural polymers. Adv Drug Deliv Rev. 2022;191: 114589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2022.114589</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Shen M, Song Q, Xie J. Biological activities and pharmaceutical applications of polysaccharide from natural resources: a review. Carbohydr Polym. 2018;183:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2017.12.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou X, Zhong D, Chen H, Gu Z, Gong Q, Ma X, Zhang H, Zhu H, Luo K. Recent advances in hyaluronic acid-based nanomedicines: preparation and application in cancer therapy. Carbohydr Polym. 2022;292: 119662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2022.119662</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimatteo R, Darling NJ, Segura T. In situ forming injectable hydrogels for drug delivery and wound repair. Adv Drug Deliv Rev. 2018;127:167&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2018.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Melke J, Midha S, Ghosh S, Ito K, Hofmann S. Silk fibroin as biomaterial for bone tissue engineering. Acta Biomater. 2016;31:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2015.09.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH. Protein-Based Nanoparticles as Drug Delivery Systems. Pharmaceutics. 2020;12(7):604.</Citation></Reference><Reference><Citation>Song X, Jiang Y, Zhang W, Elfawal G, Wang K, Jiang D, Hong H, Wu J, He C, Mo X, Wang H. Transcutaneous tumor vaccination combined with anti-programmed death-1 monoclonal antibody treatment produces a synergistic antitumor effect. Acta Biomater. 2022;140:247&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2021.11.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassani GA, Vincoli V, Biagiotti M, Valsecchi E, Zucca MV, Clavelli C, Alessandrino A, Freddi G. A Route to Translate a Silk-Based Medical Device from Lab to Clinic: The Silk Biomaterials Srl Experience. Insects. 2022;13(2):212.</Citation></Reference><Reference><Citation>Foox M, Zilberman M. Drug delivery from gelatin-based systems. Expert Opin Drug Deliv. 2015;12:1547&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2015.1037272</ArticleId></ArticleIdList></Reference><Reference><Citation>Elzoghby AO. Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. J Control Release. 2013;172:1075&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2013.09.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh E, Oh JE, Hong J, Chung Y, Lee Y, Park KD, Kim S, Yun CO. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy. J Control Release. 2017;259:115&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2017.03.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Lei S, Liu M, Li D, Huang Y, Hu X, Yang J, Li J, Fu M, Zhang M, Wang F, Li J, Men K, Wang W. Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice. Biomaterials. 2022;291: 121872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2022.121872</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv. 2011;8:343&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2011.554818</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;108:10980&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1106634108</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin M, Du G, Sun X. Biomimetic cell-derived nanocarriers for modulating immune responses. Biomater Sci. 2020;8:530&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9BM01444F</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierig&#xe8; F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev. 2008;60:286&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2007.08.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Xuan M, Shao J, Li J. Cell membrane-covered nanoparticles as biomaterials. Natl Sci Rev. 2019;6:551&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwz037</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid ME, Mohandas N. Red blood cell blood group antigens: structure and function. Semin Hematol. 2004;41:93&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminhematol.2004.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobkin J, Mangalmurti NS. Immunomodulatory roles of red blood cells. Curr Opin Hematol. 2022;29:306&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOH.0000000000000734</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q, Zhang Y, Li Z, Hou X, Feng N. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B. 2019;9:675&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2019.01.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A. 2014;111:E3053-3061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1411082111</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehaini D, Wei X, Fang RH, Masson S, Angsantikul P, Luk BT, Zhang Y, Ying M, Jiang Y, Kroll AV, Gao W, Zhang L. Erythrocyte-Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization. Adv Mater. 2017;29(16). https://doi.org/10.1002/adma.201606209 .</Citation></Reference><Reference><Citation>Christie C, Madsen SJ, Peng Q, Hirschberg H. Macrophages as nanoparticle delivery vectors for photothermal therapy of brain tumors. Ther Deliv. 2015;6:371&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde.14.121</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011;20:5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368910X</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53: e12712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cpr.12712</ArticleId></ArticleIdList></Reference><Reference><Citation>Szydlak R. Mesenchymal stem cells&#x2019; homing and cardiac tissue repair. Acta Biochim Pol. 2019;66:483&#x2013;9.</Citation></Reference><Reference><Citation>Yang N, Ding Y, Zhang Y, Wang B, Zhao X, Cheng K, Huang Y, Taleb M, Zhao J, Dong WF, Zhang L, Nie G. Surface functionalization of polymeric nanoparticles with umbilical cord-derived mesenchymal stem cell membrane for tumor-targeted therapy. ACS Appl Mater Interfaces. 2018;10:22963&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.8b05363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao L, Bu LL, Cai B, Xu JH, Li A, Zhang WF, Sun ZJ, Guo SS, Liu W, Wang TH, Zhao XZ. Cancer cell membrane-coated upconversion nanoprobes for highly specific tumor imaging. Adv Mater. 2016;28:3460&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201506086</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang RH, Hu CM, Luk BT, Gao W, Copp JA, Tai Y, O&#x2019;Connor DE, Zhang L. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14:2181&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nl500618u</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerritzen MJH, Martens DE, Wijffels RH, van der Pol L, Stork M. Bioengineering bacterial outer membrane vesicles as vaccine platform. Biotechnol Adv. 2017;35:565&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biotechadv.2017.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Laughlin RC, Alaniz RC. Outer membrane vesicles in service as protein shuttles, biotic defenders, and immunological doppelg&#xe4;ngers. Gut Microbes. 2016;7:450&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2016.1222345</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim OY, Park HT, Dinh NTH, Choi SJ, Lee J, Kim JH, Lee SW, Gho YS. Bacterial outer membrane vesicles suppress tumor by interferon-&#x3b3;-mediated antitumor response. Nat Commun. 2017;8:626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00729-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Yao S, Hu Y, Zhao X, Lee RJ. Application of lipid-based nanoparticles in cancer immunotherapy. Front Immunol. 2022;13: 967505.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.967505</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ma Y, Zhang J, Kuo JC, Zhang Z, Xie H, Zhu J, Liu T. Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy. Molecules. 2022;27(6):1943.</Citation></Reference><Reference><Citation>Liu JQ, Zhang C, Zhang X, Yan J, Zeng C, Talebian F, Lynch K, Zhao W, Hou X, Du S, Kang DD, Deng B, McComb DW, Bai XF, Dong Y. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J Control Release. 2022;345:306&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2022.03.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C, Duan S, Ye F, Hou X, Li X, Zhao J, Yu X, Hu Z, Tang Z, Mo F, Yang X, Lu X. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. Theranostics. 2018;8:1723&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.22056</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Moignic A, Malard V, Benvegnu T, Lemi&#xe8;gre L, Berchel M, Jaffr&#xe8;s PA, Baillou C, Delost M, Macedo R, Rochefort J, Lescaille G, Pichon C, Lemoine FM, Midoux P, Mateo V. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells. J Control Release. 2018;278:110&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2018.03.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Qiu M, Ye Z, Nyalile T, Li Y, Glass Z, Zhao X, Yang L, Chen J, Xu Q. In situ cancer vaccination using lipidoid nanoparticles. Sci Adv. 2021;7(19):eabf1244.</Citation></Reference><Reference><Citation>Poschenrieder ST, Schiebel SK, Castiglione K. Stability of polymersomes with focus on their use as nanoreactors. Eng Life Sci. 2018;18:101&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/elsc.201700009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheoran R, Khokra SL, Chawla V, Dureja H. Recent patents, formulation techniques, classification and characterization of liposomes. Recent Pat Nanotechnol. 2019;13:17&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1872210513666181127110413</ArticleId></ArticleIdList></Reference><Reference><Citation>Karal MAS, Nasrin T, Ahmed M, Ahamed MK, Ahammed S, Akter S, Hasan S, Mahbub ZB. A new purification technique to obtain specific size distribution of giant lipid vesicles using dual filtration. PLoS One. 2021;16: e0254930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ourani-Pourdashti S, Mirzaei E, Heidari R, Ashrafi H, Azadi A. Preparation and evaluation of niosomal chitosan-based in situ gel formulation for direct nose-to-brain methotrexate delivery. Int J Biol Macromol. 2022;213:1115&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.06.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaafar-Maalej C, Diab R, Andrieu V, Elaissari A, Fessi H. Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation. J Liposome Res. 2010;20:228&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08982100903347923</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Zhang J, Liao Y, Alakpa EV, Bunpetch V, Zhang J, Ouyang H. Current advances in microsphere based cell culture and tissue engineering. Biotechnol Adv. 2020;39: 107459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biotechadv.2019.107459</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Chen Y, Hong X, Liu Z, Yuan W. Porous microsphere and its applications. Int J Nanomedicine. 2013;8:1111&#x2013;20.</Citation></Reference><Reference><Citation>Clark ST, Arras MML, Sarles SA, Frymier PD. Modeling the saturation of detergent association in mixed liposome systems. Colloids Surf B Biointerfaces. 2021;206: 111927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2021.111927</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wang J, Yang J. The impact of dexmedetomidine-loaded nano-microsphere combined with percutaneous acupoint electrical stimulation on the postoperative cognitive function of elderly patients with hip fracture. Cell Mol Biol (Noisy-le-grand). 2022;68:77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="doi">10.14715/cmb/2022.68.3.10</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H, Li A, Man J, Li J, Li J. Fabrication of Multi-Layered Microspheres Based on Phase Separation for Drug Delivery. Micromachines (Basel). 2021;12(6):723.</Citation></Reference><Reference><Citation>Zhang ZL, Li LJ, Sun D, Wang M, Shi JR, Yang D, Wang LH, Zou SC. Preparation and properties of chitosan-based microspheres by spray drying. Food Sci Nutr. 2020;8:1933&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/fsn3.1479</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Yang Y, He L, Sun R, Pu C, Xie B, He H, Zhang Y, Yin T, Wang Y, Tang X. Injectable sustained-release depots of PLGA microspheres for insoluble drugs prepared by hot-melt extrusion. Pharm Res. 2017;34:2211&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-017-2228-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheth S, Stealey S, Morgan NY, Zustiak SP. Microfluidic chip device for in situ mixing and fabrication of hydrogel microspheres via michael-type addition. Langmuir. 2021;37:11793&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.langmuir.1c01739</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LY, Ma GH, Su ZG. Preparation of uniform sized chitosan microspheres by membrane emulsification technique and application as a carrier of protein drug. J Control Release. 2005;106:62&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2005.04.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Park EJ, Na DH. Recent progress in dendrimer-based nanomedicine development. Arch Pharm Res. 2018;41:571&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-018-1008-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesharwani P, Gothwal A, Iyer AK, Jain K, Chourasia MK, Gupta U. Dendrimer nanohybrid carrier systems: an expanding horizon for targeted drug and gene delivery. Drug Discov Today. 2018;23:300&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2017.06.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Chung TS, Chng ML. Surface characterization, modification chemistry, and separation performance of polyimide and polyamidoamine dendrimer composite films. Langmuir. 2004;20:8230&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/la049060z</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey SK, Salunkhe S, Agrawal M, Kali M, Singhvi G, Tiwari S, Saraf S, Saraf S, Alexander A. Understanding the pharmaceutical aspects of dendrimers for the delivery of anticancer drugs. Curr Drug Targets. 2020;21:528&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450120666191031092259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherje AP, Jadhav M, Dravyakar BR, Kadam D. Dendrimers: a versatile nanocarrier for drug delivery and targeting. Int J Pharm. 2018;548:707&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2018.07.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraji Rad Z, Prewett PD, Davies GJ. An overview of microneedle applications, materials, and fabrication methods. Beilstein J Nanotechnol. 2021;12:1034&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="doi">10.3762/bjnano.12.77</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Saeed Al-Japairai K, Mahmood S, Hamed Almurisi S, Reddy Venugopal J, Rebhi Hilles A, Azmana M, Raman S. Current trends in polymer microneedle for transdermal drug delivery. Int J Pharm. 2020;587:119673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2020.119673</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Xu D, Xuan X, He H. Advances of Microneedles in Biomedical Applications. Molecules. 2021;26(19):5912.</Citation></Reference><Reference><Citation>He X, Sun J, Zhuang J, Xu H, Liu Y, Wu D. Microneedle system for transdermal drug and vaccine delivery: devices, safety, and prospects. Dose Response. 2019;17:1559325819878585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1559325819878585</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F, Kong Y, Shao C, Cheng Y, Lu J, Tao Y, Du J, Wang H. Chitosan-based multifunctional flexible hemostatic bio-hydrogel. Acta Biomater. 2021;136:170&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2021.09.056</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Irvine DJ. Engineering chemoattractant gradients using chemokine-releasing polysaccharide microspheres. Biomaterials. 2011;32:4903&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2011.03.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda K, Akiba J, Ogasawara S, Todoroki K, Nakayama M, Sumi A, Kusano H, Sanada S, Suekane S, Xu K, Bae KH, Kurisawa M, Igawa T, Yano H. Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-&#x3b1; and sorafenib on renal cell carcinoma cells. Acta Biomater. 2016;29:103&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2015.10.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Y, Sun ZY, Wang Y, Zhang BD, Liu D, Li YM. Designable immune therapeutical vaccine system based on dna supramolecular hydrogels. ACS Appl Mater Interfaces. 2018;10:9310&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.8b00312</ArticleId></ArticleIdList></Reference><Reference><Citation>Pentlavalli S, Chambers P, Sathy BN, O'Doherty M, Chalanqui M, Kelly DJ, Haut-Donahue T, McCarthy HO, Dunne NJ. Simple Radical Polymerization of Poly(Alginate-Graft-N-Isopropylacrylamide) Injectable Thermoresponsive Hydrogel with the Potential for Localized and Sustained Delivery of Stem Cells and Bioactive Molecules. Macromol Biosci. 2017;17(11). https://doi.org/10.1002/mabi.201700118 .</Citation></Reference><Reference><Citation>Kim B, Seo B, Park S, Lee C, Kim JO, Oh KT, Lee ES, Choi HG, Youn YS. Albumin nanoparticles with synergistic antitumor efficacy against metastatic lung cancers. Colloids Surf B Biointerfaces. 2017;158:157&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2017.06.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Li C. Preparation and evaluation of hemoglobin-bovine serum albumin nanoparticles with red blood cell Membrane directional coating. Sichuan Da Xue Xue Bao Yi Xue Ban. 2021;52:624&#x2013;9.</Citation></Reference><Reference><Citation>Lei C, Liu XR, Chen QB, Li Y, Zhou JL, Zhou LY, Zou T. Hyaluronic acid and albumin based nanoparticles for drug delivery. J Control Release. 2021;331:416&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2021.01.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi E, Shien T, Iwata H. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. Jpn J Clin Oncol. 2021;51:321&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jjco/hyaa230</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall CM, Weiden J, Eggermont LJ, Figdor CG. Dendritic cells in cancer immunotherapy. Nat Mater. 2018;17:474&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41563-018-0093-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Guevara ML, Persano F, Persano S. Nano-immunotherapy: overcoming tumour immune evasion. Semin Cancer Biol. 2021;69:238&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2019.11.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Wang Y, Gao J, Saeed M, Li T, Wang W, Yu H. Nanobiomaterial-based vaccination immunotherapy of cancer. Biomaterials. 2021;270: 120709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2021.120709</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh T, Shojaosadati SA. Multifunctional nanoparticles for cancer immunotherapy. Hum Vaccin Immunother. 2016;12:1863&#x2013;75.</Citation></Reference><Reference><Citation>Zhang Y, Xu H, Jiang L, Liu Z, Lian C, Ding X, Wan C, Liu N, Wang Y, Yu Z, Zhu L, Yin F, Li Z. Sulfonium-driven neoantigen-released DNA nanodevice as a precise vaccine for tumor immunotherapy and prevention. ACS Nano. 2022;16:19509&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.2c09708</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Fan JX, Zheng DW, Zhang XZ. Tumor antigen loaded nanovaccine induced NIR-Activated inflammation for enhanced antigen presentation during immunotherapy of tumors. Small. 2022;18(49):e2205193.</Citation></Reference><Reference><Citation>Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.07.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen F, Feng L, Zhu Y, Tao D, Xu J, Peng R, Liu Z. Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer. Biomaterials. 2020;255: 120190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2020.120190</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetab Boushehri MA, Stein V, Lamprecht A. Cargo-free particles of ammonio methacrylate copolymers: From pharmaceutical inactive ingredients to effective anticancer immunotherapeutics. Biomaterials. 2018;166:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2018.02.053</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54:859&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.01.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, You X, Wang X, Cui L, Wang Z, Xu F, Li M, Yang Z, Liu J, Huang P, Kang Y, Wu J, Xia X. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc Natl Acad Sci U S A. 2021;118(6):e2005191118.</Citation></Reference><Reference><Citation>Liang Q, Zhou L, Li Y, Liu J, Liu Y. Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation. J Drug Target. 2022;30:119&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1061186X.2021.1927056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji C, Si J, Xu Y, Zhang W, Yang Y, He X, Xu H, Mou X, Ren H, Guo H. Mitochondria-targeted and ultrasound-responsive nanoparticles for oxygen and nitric oxide codelivery to reverse immunosuppression and enhance sonodynamic therapy for immune activation. Theranostics. 2021;11:8587&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.62572</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Musetti SN, Huang L. Nanomaterials for cancer immunotherapy. Biomaterials. 2017;148:16&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2017.09.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang Y, Tsai YC, Wang CC, Hsueh FJ, Huang CY, Chung SD, Chen CH, Pu YS, Cheng JC. Tumor-derived C-C motif ligand 2 induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer cells in the postirradiated microenvironment. Int J Radiat Oncol Biol Phys. 2022;114:321&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2022.06.054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TH, Kang MS, Mandakhbayar N, El-Fiqi A, Kim HW. Anti-inflammatory actions of folate-functionalized bioactive ion-releasing nanoparticles imply drug-free nanotherapy of inflamed tissues. Biomaterials. 2019;207:23&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2019.03.034</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Peng M, Lu R, Meng X, Liang W, Li Z, Qiu M, Zhang B, Nie G, Xie N, Zhang H, Prasad PN. Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy. Light Sci Appl. 2020;9:161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41377-020-00388-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang A, Sheng S, Bai Y, Xing G, Yu X, Zhu D, Mei L, Dong X, Lv F. Hydrogel/nanoparticles-mediated cooperative combination of antiangiogenesis and immunotherapy. Acta Biomater. 2022;153:124&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2022.09.060</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Wu J. Three-dimensional (3D) scaffolds as powerful weapons for tumor immunotherapy. Bioactive Materials. 2022;17:300&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2022.01.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancato V, Oliveira JM, Correlo VM, Reis RL, Kundu SC. Could 3D models of cancer enhance drug screening? Biomaterials. 2020;232: 119744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2019.119744</ArticleId></ArticleIdList></Reference><Reference><Citation>Florczyk SJ, Liu G, Kievit FM, Lewis AM, Wu JD, Zhang M. 3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro. Adv Healthc Mater. 2012;1:590&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.201100054</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrella A, Dondero A, Aiello M, Casu B, Olive D, Regis S, Bottino C, Pende D, Meazza R, Caluori G, Castriconi R, Scaglione S. Cell-laden hydrogel as a clinical-relevant 3D model for analyzing neuroblastoma growth, immunophenotype, and susceptibility to therapies. Front Immunol. 1876;2019:10.</Citation></Reference><Reference><Citation>Singh A. Biomaterials innovation for next generation ex vivo immune tissue engineering. Biomaterials. 2017;130:104&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2017.03.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Pingale P, Dawre S, Dhapte-Pawar V, Dhas N, Rajput A. Advances in 4D printing: from stimulation to simulation. Drug Deliv Transl Res. 2023;13:164&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-022-01200-y</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
  recorded_at: Wed, 17 May 2023 09:04:11 GMT
recorded_with: VCR 6.1.0
